154 related articles for article (PubMed ID: 36221984)
1. Oral Mercaptopurine Adherence in Pediatric Acute Lymphoblastic Leukemia: A Survey Study From the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.
Kahn JM; Stevenson K; Beauchemin M; Koch VB; Cole PD; Welch JJG; Gage-Bouchard E; Karsenty C; Silverman LB; Kelly KM; Bona K
J Pediatr Hematol Oncol Nurs; 2023; 40(1):17-23. PubMed ID: 36221984
[No Abstract] [Full Text] [Related]
2. Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
Hoppmann AL; Chen Y; Landier W; Hageman L; Evans WE; Wong FL; Relling MV; Bhatia S
Cancer; 2021 Oct; 127(20):3832-3839. PubMed ID: 34161608
[TBL] [Abstract][Full Text] [Related]
3. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
[TBL] [Abstract][Full Text] [Related]
4. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.
Bhatia S; Landier W; Hageman L; Kim H; Chen Y; Crews KR; Evans WE; Bostrom B; Casillas J; Dickens DS; Maloney KW; Neglia JP; Ravindranath Y; Ritchey AK; Wong FL; Relling MV
Blood; 2014 Oct; 124(15):2345-53. PubMed ID: 24829202
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
7. Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
Landier W; Chen Y; Hageman L; Kim H; Bostrom BC; Casillas JN; Dickens DS; Evans WE; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
Blood; 2017 Apr; 129(14):1919-1926. PubMed ID: 28153823
[TBL] [Abstract][Full Text] [Related]
8. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
9. Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study.
Psihogios AM; Li Y; Ahmed A; Huang J; Kersun LS; Schwartz LA; Barakat LP
Pediatr Blood Cancer; 2021 Feb; 68(2):e28767. PubMed ID: 33073479
[TBL] [Abstract][Full Text] [Related]
10. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.
Bhatia S; Landier W; Shangguan M; Hageman L; Schaible AN; Carter AR; Hanby CL; Leisenring W; Yasui Y; Kornegay NM; Mascarenhas L; Ritchey AK; Casillas JN; Dickens DS; Meza J; Carroll WL; Relling MV; Wong FL
J Clin Oncol; 2012 Jun; 30(17):2094-101. PubMed ID: 22564992
[TBL] [Abstract][Full Text] [Related]
11. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
12. How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic.
Kahn JM; Athale UH; Clavell LA; Cole PD; Leclerc JM; Laverdiere C; Michon B; Schorin MA; Welch JJ; Sallan SE; Silverman LB; Kelly KM
J Pediatr Health Care; 2017; 31(1):e1-e6. PubMed ID: 27461368
[TBL] [Abstract][Full Text] [Related]
13. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
15. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
16. Optimizing medication adherence in children with cancer.
Gupta S; Bhatia S
Curr Opin Pediatr; 2017 Feb; 29(1):41-45. PubMed ID: 27798425
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review.
Zeng XL; Heneghan MB; Badawy SM
Curr Oncol; 2023 Jan; 30(1):720-748. PubMed ID: 36661705
[TBL] [Abstract][Full Text] [Related]
18. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis.
Wu YP; Stenehjem DD; Linder LA; Yu B; Parsons BG; Mooney R; Fluchel MN
J Pediatr Oncol Nurs; 2018; 35(2):86-93. PubMed ID: 29188741
[TBL] [Abstract][Full Text] [Related]
20. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
